Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
نویسندگان
چکیده
Diabetes is the most common cause of CKD (chronic kidney disease). also one important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class medication used to lower high blood level in people with type 2 diabetes. In researches demonstrated a significant and clinically relevant reduction risks albuminuria progression nephropathy, doubling serum creatinine levels, initiation renal replacement therapy. This review focuses on therapeutic effectiveness using for treatment
منابع مشابه
the impact of e-readiness on ec success in public sector in iran the impact of e-readiness on ec success in public sector in iran
acknowledge the importance of e-commerce to their countries and to survival of their businesses and in creating and encouraging an atmosphere for the wide adoption and success of e-commerce in the long term. the investment for implementing e-commerce in the public sector is one of the areas which is focused in government‘s action plan for cross-disciplinary it development and e-readiness in go...
The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease
There is a need for treatment options in patients with type 2 diabetes mellitus and kidney disease to achieve glucose targets without risk of hypoglycemia. This article describes management options for these patients using glucose-lowering therapies, in particular dipeptidyl peptidase-4 inhibitors.
متن کاملPractical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential b...
متن کاملUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetes
The importance of the kidney's role in glucose homeostasis has gained wider understanding in recent years. Consequently, the development of a new pharmacological class of anti-diabetes agents targeting the kidney has provided new treatment options for the management of type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT2) inhibitors, such as dapagliflozin, canagliflozin,...
متن کاملSGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
Despite the availability of a great variety of medications, a significant proportion of people with type 2 diabetes mellitus (T2DM) are not able to achieve or maintain adequate glycemic control. Beyond improved glucose control, novel treatments would ideally provide a reduction of cardiovascular risk, with a favorable impact on excess weight, and a low intrinsic hypoglycemia risk, as well as a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Education, Health and Sport
سال: 2022
ISSN: ['2391-8306']
DOI: https://doi.org/10.12775/jehs.2022.12.09.036